This content is protected against AI scraping.
On March 31, a U.S. District Court judge denied a motion by the group Smart Approaches to Marijuana (SAM) to block a new federal pilot program that allows Medicare to cover hemp-derived CBD products for older Americans. Orchestrated by CMS Administrator Mehmet Oz under a directive from President Trump, the program provides up to $500 in annual coverage for oral CBD products as a non-opioid alternative for pain management. The court ruled that SAM failed to meet the high legal bar required for an emergency restraining order, allowing the program to launch on April 1.
SAM’s lawsuit characterizes the initiative as an “anti-science” violation of federal law, arguing that CMS exceeded its authority by sanctioning substances they claim are dangerous and mislabeled. The group further contends the program bypasses necessary administrative procedures and conflicts with upcoming 2026 hemp regulations. While the program is currently active, a preliminary injunction hearing is set for April 20 to further debate the legality and public health implications of the policy.
This is a summary. Read the original article here.
Original article written by Tony Lange. Published April 1, 2026 by Cannabis Business Times.







